On March 14, 2022, Shanghai UniXell Biotechnology Co., Ltd. (hereinafter referred to as "UniXell "), a leading company dedicated to the development of pluripotent stem cell drugs, announced the completion of nearly 200 million yuan in financing. This round of financing is led by Sherpa Investment, co-led by CDH VGC (Innovation and Growth Fund), and co-invested by Taifu Capital, Kunlun Capital, Hillhouse Venture Capital, Fosun Pharma, Ruihua Capital and Guofang Capital.